Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)

Zomedica Corp.

Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.
Gross margin 68% for year; Q4 69% best quarter. Adjusted EBITDA loss improved to $17.1M from $20.2M.
Cash burn reduced to $18.1M for year, $1.1M in Q4; cash/securities $53.3M.
Consumable revenue grew 16% to $20.7M; Development Services segment contributed $3.1M.
Net loss $81.9M includes $55.8M non-cash impairment; operating expenses ex-impairment down 7%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.